These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 38448909)

  • 21. A systematic review of empirical bioethics methodologies.
    Davies R; Ives J; Dunn M
    BMC Med Ethics; 2015 Mar; 16():15. PubMed ID: 25885575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
    Hashem F; Calnan MW; Brown PR
    Health Expect; 2018 Feb; 21(1):128-137. PubMed ID: 28686809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Flexibility in assessment of rare disease technologies via NICE's single technology appraisal route: a thematic analysis.
    Hale G; Morris J; Barker-Yip J
    J Comp Eff Res; 2023 Nov; 12(11):e230093. PubMed ID: 37724717
    [No Abstract]   [Full Text] [Related]  

  • 24. A defense of the common morality.
    Beauchamp TL
    Kennedy Inst Ethics J; 2003 Sep; 13(3):259-74. PubMed ID: 14577460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Evolving Nature of Health Technology Assessment: A Critical Appraisal of NICE's New Methods Manual.
    Angelis A; Harker M; Cairns J; Seo MK; Legood R; Miners A; Wiseman V; Chalkidou K; Grieve R; Briggs A
    Value Health; 2023 Oct; 26(10):1503-1509. PubMed ID: 37268059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A theory of international bioethics: multiculturalism, postmodernism, and the bankruptcy of fundamentalism.
    Baker R
    Kennedy Inst Ethics J; 1998 Sep; 8(3):201-31. PubMed ID: 11656932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Views of Directors of Public Health about NICE Appraisal Guidance: results of a postal survey. National Institute for Clinical Excellence.
    Davies E; Littlejohns P
    J Public Health Med; 2002 Dec; 24(4):319-25. PubMed ID: 12546211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Challenge for Orphan Drugs Remains: Three Case Studies Demonstrating the Impact of Changes to NICE Methods and Processes and Alternative Mechanisms to Value Orphan Products.
    Lee D; McCarthy G; Saeed O; Allen R; Malottki K; Chandler F
    Pharmacoecon Open; 2023 Mar; 7(2):175-187. PubMed ID: 36315388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An analysis of NICE's 'restricted' (or 'optimized') decisions.
    O'Neill P; Devlin NJ
    Pharmacoeconomics; 2010; 28(11):987-93. PubMed ID: 20936882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative Assessment of Reimbursement Recommendations by NICE and HAS for Oncology New Medicines Indicated for the Treatment of Solid Tumors from 2015 to 2021.
    Trouiller JB; Laramée P
    Med Decis Making; 2023; 43(7-8):961-972. PubMed ID: 37480275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?
    Sculpher M; Palmer S
    Pharmacoeconomics; 2020 Mar; 38(3):247-257. PubMed ID: 31930460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Influence of Cost-Effectiveness and Other Factors on Nice Decisions.
    Dakin H; Devlin N; Feng Y; Rice N; O'Neill P; Parkin D
    Health Econ; 2015 Oct; 24(10):1256-1271. PubMed ID: 25251336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Audit of data redaction practices in NICE technology appraisals from 1999 to 2019.
    Osipenko L
    BMJ Open; 2021 Oct; 11(10):e051812. PubMed ID: 34615680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Defending secular clinical ethics expertise from an Engelhardt-inspired sense of theoretical crisis.
    Brummett A
    Theor Med Bioeth; 2022 Feb; 43(1):47-66. PubMed ID: 35366754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective.
    Dunlop W; van Keep M; Elroy P; Perez ID; Ouwens MJNM; Sarbajna T; Zhang Y; Greystoke A
    Pharmacoecon Open; 2022 Mar; 6(2):241-252. PubMed ID: 34532842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Review of Economic Models Submitted to NICE's Technology Appraisal Programme, for Treatments of T1DM & T2DM.
    Daly MJ; Elvidge J; Chantler T; Dawoud D
    Front Pharmacol; 2022; 13():887298. PubMed ID: 35645790
    [No Abstract]   [Full Text] [Related]  

  • 38. Bioethics of life programs: taking seriously moral pluralism in clinical settings.
    Niebroj L
    Eur J Med Res; 2010 Nov; 15 Suppl 2(Suppl 2):98-101. PubMed ID: 21147632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal.
    Kilonzo M; Hislop J; Elders A; Fraser C; Bissett D; McClinton S; Mowatt G; Vale L
    Pharmacoeconomics; 2013 Jan; 31(1):15-24. PubMed ID: 23329590
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.